Market Intelligence, Clinical Progress, and High-Purity Reagents for Achondroplasia and Cardiovascular Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for NPR2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | NPR2 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View NPR2 Products |
| Gene Delivery | NPR2 Lentivirus Full-length ORF for stable cell line generation. Ideal for cGMP reporter assays. |
View NPR2 Products |
| Benchmark Ab | Anti-NPR2 (Reference Clone) / CNP Analog Recombinant positive control. Theoretical MW verified. |
View NPR2 Products |
| Validator | NPR2 siRNA Set For knockdown verification and specificity checks. |
View NPR2 Products |
| Related Target A | NPR1 (NPR-A) Counter-screening for natriuretic peptide receptor family selectivity. |
View NPR1 Products |
| Related Target B | NPR3 (NPR-C) Clearance receptor modulation and ligand availability pathway. |
View NPR3 Products |
| Related Target C | FGFR3 Pathogenic driver in achondroplasia; intersecting signaling axis with NPR2. |
View FGFR3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Preserving Intracellular Guanylate Cyclase Activity | Lentivirus Premade Particles for stable cell line generation (Crucial for downstream cGMP accumulation assays). |
| Receptor Subfamily Cross-Reactivity (NPR1 vs NPR3) | Homolog panel ECD proteins strictly verified by mass spec, ensuring absolute sequence identity. |
| Lack of Reliable Controls | Reference peptides and benchmark antibodies included, featuring rigorous Endotoxin Controlled batches. |
| False Positives in Endogenous Screening | Validated siRNA included for rapid specificity checks in target-expressing tissue lines. |
| Cross-species Translation | Human, Mouse, and Cynomolgus NPR2 orthologs available; Sequence Verified for epitope conservation. |
| Ligand Competition (CNP binding) | High-affinity ECD-Fc format optimized for competition binding assays. |
Live NPR2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Functional Domains & Key Mutations
NPR2 (Natriuretic Peptide Receptor 2) is a transmembrane receptor with two key functional domains: a Protein kinase domain and a Guanylate cyclase domain (UniProt P20594). Key mutations include:
- AMD1 mutation (rs28931581): Associated with acromesomelic dysplasia, type Maroteaux.
- SNSK1 mutations (VAR_074678, VAR_074679): Dominant negative mutations causing loss of C-type natriuretic peptide-induced signaling.
These mutations underscore the importance of using full-length constructs (e.g., lentivirus) for functional assays that preserve the native conformation of both kinase and cyclase domains.
Global Clinical Landscape & Future Outlook
The race for NPR2 therapeutics is intensifying, with major players shifting focus from daily-injected native CNP analogs to long-acting engineered peptides and novel small molecule agonists. As first-generation therapies for skeletal dysplasias (such as Achondroplasia) reach the clinic and achieve commercial success, the next wave of R&D is targeting extended half-life formulations, oral delivery systems, and expanded indications including severe cardiovascular and fibrotic diseases. The clinical precedent set by Vosoritide (BioMarin) provides a clear regulatory path for next-generation candidates.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Engineered Peptides | BioMarin, Ascendis Pharma | Achondroplasia | Selectivity Assay vs NPR3 (Need high-purity ECD-Fc) |
| Small Molecule Agonists | Novo Nordisk, Ipsen | Skeletal Dysplasias, Short Stature | cGMP Functional Assay (Need Lentivirus for Stable Cell Lines) |
| Gene Therapy | Emerging Biotechs | Severe Dwarfism Syndromes | Transduction Efficiency (Need Sequence Verified ORFs) |
| Biologics (mAb/ScFv) | Early Stage | Oncology (vascular normalization) | Internalization Assay (Need full-length Lentivirus cell line for flow cytometry) |